Navigation Links
Ventana to partner with Incyte on the development of Companion Diagnostic tests
Date:11/5/2013

TUCSON, Ariz., Nov. 5, 2013 /PRNewswire/ -- Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, today announced that it has entered into an agreement with Incyte Corporation to collaborate on the development of companion diagnostic tests for Incyte's oncology drug programs, beginning with the Incyte IDO1 inhibitor program.  As part of the agreement, Ventana will support Incyte's personalized medicine healthcare strategies for cancer drug development using its vast expertise in companion diagnostics, immunohistochemistry technology platforms, and worldwide customer support network.

Companion Diagnostics, meaning tests paired with drug therapies, help physicians identify those patients with specific biomarkers who may respond to certain types of targeted drug treatment.  Incorporating a companion diagnostic strategy into a drug development program may expedite the approval process and help generate better drugs with improved safety profiles for patients.

"With the advancement of INCB24360 into multiple Phase 2 studies, our first-in-class IDO1 inhibitor program was a logical place to begin to incorporate potential companion diagnostics.  We chose to partner with Ventana based on their strong scientific knowledge and development expertise in this area," stated Victor Sandor, MD, CM, Incyte's Group Vice President, Clinical Development.

"We are pleased that Incyte shares our passion of enabling personalized medicine for cancer patients worldwide and look forward to pursuing many successful drug development programs together," says Mara G. Aspinall, President, Ventana Medical Systems, Inc.

In addition to Incyte, Ventana has worked with more than 45 biopharmaceutical partners over the past decade and is currently engaged in more than 150 collaborative projects to develop and commercialize companion diagnostics globally.

About Ventana Medical Systems, Inc.

Ventana Medical Systems, Inc. ("VMSI") (SIX: RO, ROG; OTCQX: RHHBY), a member of the Roche Group, innovates and manufactures instruments and reagents that automate tissue processing and slide staining for cancer diagnostics. VENTANA products are used in clinical histology and drug development research laboratories worldwide. The company's intuitive, integrated staining, workflow management platforms, and digital pathology solutions optimize laboratory efficiencies to reduce errors, support diagnosis and inform treatment decisions for anatomic pathology professionals. Together with Roche, VMSI is driving Personalized Healthcare through accelerated drug discovery and the development of "companion diagnostics" to identify the patients most likely to respond favorably to specific therapies. Visit http://ventana.com/ to learn more.

VENTANA and the VENTANA logo are trademarks of Roche.

VMSI Media Relations
Jacqueline Bucher
Senior Director, Corporate Communications
Phone: 520-877-7288
e-mail: Jacquie Bucher


'/>"/>
SOURCE Ventana Medical Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Ventana Receives FDA Clearance for p53 (DO-7) Image Analysis and Digital Read Applications
2. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
3. Ventana Supports World Patient Safety Day, July 25
4. Ventana Medical Systems, Inc. develops first-ever fully automated dual-stain technique for miRNA and protein detection in cancer
5. MedeAnalytics Receives Leadership Award from Ventana Research
6. Ventana and Biocare Medical sign p63 license agreement to aid in the differential diagnosis of benign and malignant prostate lesions
7. Ventana and Barco revolutionize digital pathology viewing experience
8. Ventana and EMC join forces to take digital pathology into the world of Big Data
9. Ventana receives approval from Chinas FDA for first fully automated IHC companion diagnostic identifying ALK protein expression in lung cancer patients
10. Ventana launches fully automated Gram Stain on the BenchMark Special Stains platform
11. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2017)... PROVIDENCE, R.I. , Sept. 18, 2017 ... in the fields of bioinformatics and immune ... to develop a protective avian influenza A (H7N9) vaccine. ... is distantly related to seasonal influenza and ... approaches, which rely on prior exposure to be ...
(Date:9/12/2017)... , Sept. 12, 2017   EcoVadis , the leading platform ... published the first annual edition of its Global CSR Risk and Performance ... evaluated by EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data ... ... ...
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... N.J. (PRWEB) , ... October 13, 2017 , ... The ... Holly Day Market. Featuring a collection of specialty vendors and unique items from across ... personalized and quality-focused health and wellness services offered by the VNA. The boutique ...
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Planet Fitness, ... the U.S., announced today its plans to open a flagship location in Covington, LA ... the former Rooms To Go store next to Office Depot in the Holiday Square ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):